Picture Berlin Partner German Biotech Days 2024 in Berlin 650x100px
Organisation › Details

AAVantgarde Bio S.r.l.

AAVantgarde Bio, a clinical stage Milan-based international biotechnology start-up that has developed proprietary Adeno-Associated Viral (AAV) vector platforms that allow for the delivery of large genes for inherited retinal disorders. Co-founded by Professor Alberto Auricchio and originating from the research activities carried out at Tigem (Telethon Institute of Genetics and Medicine) in Naples, Italy, and supported by Sofinnova Partners. AAVantgarde’s platforms are focused on broadening the application of AAV based therapies by addressing the limitations of single AAV therapies cargo capacity. Approximately 1,200 ocular and non-ocular human coding sequences are above standard AAV carrying capacity and could be leveraged using our platform technology. *


Period Start 2022-09-08 existent
Products Industry gene therapy
  Industry 2 adeno-associated viral vector (AAV vector)
Region Region Milano (Milan)
  Country Italy
  Street 18 Via Uberto Visconti di Modrone
  City 20122 Milano (MI)
  Tel +39-329-552-4297
    Address record changed: 2024-04-03
Basic data Employees n. a.
    * Document for »About Section«: AAVantgarde Bio S.r.l.. (9/8/22). "Press Release: AAVantgarde Bio Appoints Dr. Natalia Misciattelli as Chief Executive Officer". Milan.
Record changed: 2024-04-03


Picture EBD Group World of Partnering Opportunities 650x200px

More documents for AAVantgarde Bio S.r.l.

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]


Picture Berlin Partner Top News Bayer Aignostics Collaboration 650x300px

» top